Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

NCT03634150 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Patients were screened but not enrolled

Conditions

Metastatic Ovarian Cancer
Triple Negative Breast Cancer

Interventions

BIOLOGICAL: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.

Sponsor

Immune System Key Ltd